Invention Grant
- Patent Title: Protein kinase C inhibitors and methods of their use
-
Application No.: US16354416Application Date: 2019-03-15
-
Publication No.: US10508101B2Publication Date: 2019-12-17
- Inventor: Michael Joseph Luzzio , Julien Papillon , Michael Scott Visser
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agency: Schwegman Lundberg & Woessner, P.A.
- Main IPC: A61K31/497
- IPC: A61K31/497 ; C07D401/14 ; C07D413/14 ; A61P31/04 ; A61K31/506 ; A61P35/00 ; A61K45/06
Abstract:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
Public/Granted literature
- US20190202809A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Public/Granted day:2019-07-04
Information query
IPC分类:
